NCT05978726View on ClinicalTrials.gov

Ticagrelor Versus Clopidogrel for CMD in Patients With AMI: A Retrospective Study Based on the Angio-IMR

CompletedOBSERVATIONAL
Enrollment

325

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

May 30, 2020

Study Completion Date

May 30, 2022

Conditions
Coronary Heart Disease
Interventions
DRUG

Dual antiplatelet therapy with aspirin and either ticagrelor or clopidogrel

Patients with acute myocardial infarction randomly received dual antiplatelet therapy with with aspirin 100mg daily and either ticagrelor 90mg twice daily or clopidogrel 75mg once daily for at least 9 months after PCI as needed.

Trial Locations (1)

310009

Second affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT05978726 - Ticagrelor Versus Clopidogrel for CMD in Patients With AMI: A Retrospective Study Based on the Angio-IMR | Biotech Hunter | Biotech Hunter